Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MenACYW conjugate vaccine

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Neisseria meningitidis serogroups A, C, W, Y capsular polysaccharides · developed by Sanofi Pasteur, a Sanofi Company

Phase 3 Most advanced trial (none active)
SNY Developer

What is MenACYW conjugate vaccine?

MenACYW conjugate vaccine is a meningococcal vaccine given by intramuscular injection, intended to induce immunity against Neisseria meningitidis serogroups A, C, W and Y. It is being studied for meningococcal infection in healthy volunteers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MenQuadfi
Drug type
Vaccine (Recombinant protein vaccine)
Targets
Neisseria meningitidis serogroups A, C, W, Y capsular polysaccharides (antigen)
Mechanism
Immune activation, directed at Neisseria meningitidis serogroups A, C, W, Y capsular polysaccharides
Therapy area
Infectious disease
Developer
Sanofi Pasteur, a Sanofi Company (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

Conditions studied

Healthy VolunteersMeningococcal Infection

More from Sanofi Pasteur, a Sanofi Company

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind MenACYW conjugate vaccine

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.